STOCK TITAN

Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of - TAK STOCK NEWS

Welcome to our dedicated page for Takeda Pharmaceutical Company American Depositary Shares (each representing 1/2 of a share of news (Ticker: TAK), a resource for investors and traders seeking the latest updates and insights on Takeda Pharmaceutical Company American Depositary Shares (each representing 1/2 of a share of stock.

Takeda Pharmaceutical Company Limited (NYSE: TAK), a Japanese multinational corporation, stands as Asia's largest and one of the globe's top 20 pharmaceutical giants by revenue. Headquartered in Tokyo, Takeda operates across approximately 80 countries, merging American and British roots into its vast global presence.

With a revenue of JPY 4.3 trillion in fiscal 2023, Takeda dedicates its efforts predominantly to five therapeutic areas: oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which collectively generate more than 80% of its revenue. Takeda’s global footprint is diversified, with 50% of its revenue originating from the US, 20% from Japan, and another 20% from Europe and Canada.

Noteworthy for its robust pipeline and commitment to innovation, Takeda partners with various organizations to push the boundaries of medical research. A recent highlight includes a joint venture with Astellas Pharma Inc. and Sumitomo Mitsui Banking Corporation. This collaboration aims to incubate early drug discovery programs, striving to transition academic breakthroughs into practical medical treatments.

Moreover, Takeda's strategic partnership with Neurocrine Biosciences to develop NBI-1065845, an investigational treatment for major depressive disorder, showcases its dedication to addressing unmet medical needs. The positive Phase 2 results of the SAVITRI™ study underline the potential of NBI-1065845 to provide hope for patients with inadequate responses to existing treatments.

Takeda's philosophy focuses on creating a healthier world through life-transforming treatments in its core areas. Their values-based, R&D-driven approach has sustained their leadership in the pharmaceutical sector for over two centuries.

Rhea-AI Summary

Takeda has announced an investment of $19.5 million in FY2022, granting funds to 21 new U.S. non-profit organizations, bringing its total CSR investment to nearly $40 million. The funds aim to improve equity in health, education, and environment in under-resourced communities. Launched in FY2021, the 'Takeda Cares' program seeks sustainable change by addressing social disparities. The newly funded organizations include food banks, health equity programs, and educational initiatives across major U.S. cities such as Greater Boston, San Diego, and Atlanta. Detailed insights are available in the recently published 'Takeda Cares for Communities Report.'

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.24%
Tags
none
-
Rhea-AI Summary

Takeda announced positive results from the Phase 4 EARNEST study of vedolizumab for chronic pouchitis in the New England Journal of Medicine. The study showed that 31% of participants receiving vedolizumab achieved remission at Week 14, compared to 10% on placebo. This superiority continued with 35% remission at Week 34 versus 18% on placebo. The study confirms vedolizumab's efficacy in treating this condition, with no new safety signals reported. The commitment to alleviating chronic inflammatory gastrointestinal conditions is underscored by Takeda's focus on advancing treatment options for affected patients.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.73%
Tags
none
-
Rhea-AI Summary

Takeda (TSE:4502/NYSE:TAK) announced plans to propose Miki Tsusaka as a new independent external director at the 147th Ordinary Meeting of Shareholders on June 28, 2023. This follows the retirement announcement of Masato Iwasaki, who has served for nearly 40 years, significantly contributing to Takeda's transformation as a global biopharmaceutical leader. Tsusaka brings strong expertise from her role as President of Microsoft Japan and her previous experience at Boston Consulting Group. Takeda emphasizes its commitment to board diversity, aiming to strengthen governance and pursue its vision as a leading digital biopharmaceutical company.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.73%
Tags
management
Rhea-AI Summary

BioLife Plasma Services, part of Takeda, has opened its 200th plasma donation center in the U.S. with new locations in West Springfield, Massachusetts and Pearland, Texas. This expansion is crucial for addressing the increasing demand for life-saving plasma therapies for rare conditions. Each new center generates an estimated $4-5 million in local community contributions and creates around 70 jobs. BioLife emphasizes inclusivity in the donation process and operates over 50 bilingual centers across the U.S., enhancing accessibility for diverse communities.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.73%
Tags
none
-
Rhea-AI Summary

Takeda's TAK-279, an allosteric TYK2 inhibitor, showed promising results in a Phase 2b clinical trial for moderate-to-severe plaque psoriasis, presented on March 18, 2023, at the AAD Annual Meeting. Involving 259 patients, the trial demonstrated significant efficacy with patients on TAK-279 achieving PASI 75 (44%-67%), PASI 90 (21%-46%), and PASI 100 (10%-33%) compared to placebo (6%, 0%, 0%, respectively; p<0.001). Notably, the 2mg dose did not show significant benefits. Nimbus Therapeutics highlighted the unmet need addressed by TAK-279, steering towards further development in immune-mediated diseases.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.12%
Tags
-
Rhea-AI Summary

Takeda has announced promising results from its Phase 2b trial for TAK-279, a selective oral TYK2 inhibitor, showing significant effectiveness in treating moderate-to-severe plaque psoriasis. Patients receiving dosages of 5mg, 15mg, and 30mg achieved Psoriasis Area and Severity Index (PASI) scores of 75, 90, and 100, substantially higher than the placebo. A Phase 3 study is set to commence in FY2023, along with further evaluations in other immune-mediated diseases such as systemic lupus erythematosus and inflammatory bowel disease. The trial involved 259 patients, with mild to moderate adverse events noted.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary

Hannon Armstrong Sustainable Infrastructure Capital, Inc. (NYSE: HASI) announced the appointment of Kimberly A. Reed and Jeffrey A. Lipson to its Board of Directors effective March 1, 2023. With this change, the Board now comprises 11 members, 9 being independent. Reed, a former chairman and CEO of the U.S. Export-Import Bank, will add valuable regulatory insight and financial expertise. Lipson, who previously served as COO and CFO, assumes the CEO role, marking a leadership transition for HASI, which manages over $9 billion in assets focused on climate solutions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.46%
Tags
management
-
Rhea-AI Summary

Takeda announced significant results from the Phase 3 GRAPHITE study, demonstrating that vedolizumab significantly improved intestinal aGvHD-free survival at Day 180 after allo-HSCT, achieving a response rate of 85.5% compared to 70.9% for placebo (p<0.001). The study, presented at the 2023 Tandem Meetings, also showed no new safety signals with vedolizumab. This treatment addresses a critical unmet need in managing lower gastrointestinal aGvHD, a serious complication after stem cell transplantation. The study included 333 patients and marks an advancement in understanding vedolizumab's role in gastrointestinal inflammatory conditions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.66%
Tags
-
Rhea-AI Summary

Nimbus Therapeutics has completed the acquisition of its subsidiary Nimbus Lakshmi, Inc. by Takeda, with an upfront payment of $4 billion. This acquisition includes Nimbus's TYK2 inhibitor program, featuring the oral drug TAK-279. Nimbus anticipates receiving up to an additional $2 billion in sales-based milestone payments. The drug, designed to treat immune-mediated diseases, has shown promising results in a Phase 2b trial for moderate-to-severe plaque psoriasis, meeting its primary efficacy endpoint. Nimbus retains its pipeline for other therapies targeting cancer and autoimmune diseases.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.87%
Tags
Rhea-AI Summary

Takeda has completed the acquisition of Nimbus Lakshmi, Inc., acquiring full shares from Nimbus Therapeutics for about 4 billion USD. This significant transaction, announced on December 13, 2022, and finalized on February 8, 2023, includes acquiring the promising asset TAK-279, a selective oral TYK2 inhibitor. Phase 2b data is scheduled for release in Q4 FY2022, with a Phase 3 study aimed at psoriasis expected to commence in 2023. The acquisition enhances Takeda's late-stage pipeline, with potential applications across various immune-mediated diseases, supporting long-term growth.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.87%
Tags

FAQ

What is the current stock price of Takeda Pharmaceutical Company American Depositary Shares (each representing 1/2 of a share of (TAK)?

The current stock price of Takeda Pharmaceutical Company American Depositary Shares (each representing 1/2 of a share of (TAK) is $13.17 as of December 24, 2024.

What is the market cap of Takeda Pharmaceutical Company American Depositary Shares (each representing 1/2 of a share of (TAK)?

The market cap of Takeda Pharmaceutical Company American Depositary Shares (each representing 1/2 of a share of (TAK) is approximately 41.8B.

What are Takeda Pharmaceutical's core therapeutic areas?

Takeda focuses on oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies.

Where is Takeda Pharmaceutical headquartered?

Takeda is headquartered in Tokyo, Japan.

What recent collaborations has Takeda Pharmaceutical entered into?

Takeda recently entered a joint venture with Astellas Pharma Inc. and Sumitomo Mitsui Banking Corporation to incubate early drug discovery programs.

How diversified is Takeda's revenue geographically?

Takeda's revenue is geographically diversified: 50% from the US, 20% from Japan, and 20% from Europe and Canada.

What was Takeda's revenue in fiscal 2023?

Takeda's revenue in fiscal 2023 was JPY 4.3 trillion.

Who can benefit from Takeda's new drug NBI-1065845?

NBI-1065845 is targeted at patients with major depressive disorder who have not benefited from at least one existing antidepressant treatment.

What is the focus of Takeda’s joint venture with Astellas and Sumitomo Mitsui?

The joint venture focuses on incubating early drug discovery programs to advance academic discoveries into practical medical treatments.

How long has Takeda been in the pharmaceutical industry?

Takeda has been a leader in the pharmaceutical industry for over two centuries.

In how many countries does Takeda operate?

Takeda operates in approximately 80 countries.

How does Takeda contribute to the field of major depressive disorder treatment?

Takeda collaborates with Neurocrine Biosciences to develop NBI-1065845, an investigational treatment showing positive Phase 2 results for MDD.

Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of

NYSE:TAK

TAK Rankings

TAK Stock Data

41.75B
3.17B
0.01%
2.45%
0.18%
Drug Manufacturers - Specialty & Generic
Healthcare
Link
United States of America
Tokyo